Drug Profile


Alternative Names: RDEA-3170

Latest Information Update: 24 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ardea Biosciences
  • Developer Ardea Biosciences; AstraZeneca
  • Class Antigouts; Naphthalenes; Propionic acids; Pyridines; Small molecules
  • Mechanism of Action SLC22A12 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gout; Hyperuricaemia; Kidney disorders; Type 2 diabetes mellitus

Most Recent Events

  • 24 Oct 2017 AstraZeneca plans a phase II trial for Hyperuricaemia (Combination therapy) in USA (NCT03316131)
  • 14 Jun 2017 Updated pharmacokinetics data from a phase I trial in Gout and Hyperuricaemia presented 18th Annual Congress of the European League Against Rheumatism (EULAR-2017)
  • 14 Jun 2017 Updated pharmacokinetics and adverse events data from a phase II trial in Gout presented 18th Annual Congress of the European League Against Rheumatism (EULAR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top